Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Counsyl | RCV000190846 | SCV000800513 | uncertain significance | Mucopolysaccharidosis, MPS-III-C | 2017-04-04 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV002500583 | SCV002778424 | uncertain significance | Mucopolysaccharidosis, MPS-III-C; Retinitis pigmentosa 73 | 2022-03-08 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV002500583 | SCV003440194 | uncertain significance | Mucopolysaccharidosis, MPS-III-C; Retinitis pigmentosa 73 | 2024-06-04 | criteria provided, single submitter | clinical testing | This sequence change replaces tryptophan, which is neutral and slightly polar, with cysteine, which is neutral and slightly polar, at codon 403 of the HGSNAT protein (p.Trp403Cys). This variant is present in population databases (rs764206492, gnomAD 0.004%). This missense change has been observed in individual(s) with Mucopolysaccharidosis IIIC (PMID: 17033958, 31228227). This variant is also known as W431C. ClinVar contains an entry for this variant (Variation ID: 208817). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) has been performed at Invitae for this missense variant, however the output from this modeling did not meet the statistical confidence thresholds required to predict the impact of this variant on HGSNAT protein function. Experimental studies have shown that this missense change affects HGSNAT function (PMID: 19823584, 20583299). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Prevention |
RCV003417693 | SCV004108235 | uncertain significance | HGSNAT-related disorder | 2023-06-06 | criteria provided, single submitter | clinical testing | The HGSNAT c.1209G>T variant is predicted to result in the amino acid substitution p.Trp403Cys. To our knowledge, this variant has always been reported in cis with HGSNAT c.1843G>A (p.Trp403Cys). This haplotype was reported in the homozygous state in patients with Mucopolysaccharidosis IIIC (MPSIIIC) (Hrebicek et al. 2006. PubMed ID: 17033958, reported as p.[W431C;A643T]; Feldhammer et al. 2009. PubMed ID: 19823584). Functional studies indicated that the p.Trp403Cys variant had a >50% reduction in activity when expressed alone and resulted in complete loss of activity when expressed as a haplotype in combination with p.Ala615Thr (Fedele et al. 2010. PubMed ID: 20583299). This variant is reported in 0.0041% of alleles in individuals of African descent in gnomAD (http://gnomad.broadinstitute.org/variant/8-43046697-G-T). Although we suspect that this variant may be pathogenic, at this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. |
OMIM | RCV000190846 | SCV000245716 | pathogenic | Mucopolysaccharidosis, MPS-III-C | 2006-11-01 | no assertion criteria provided | literature only |